Max Narovlyansky PhD

Founder, CEO

Solutions for Precision Medicine:

- Microfluidics
- Biomarkers
- Point-of-care and companion diagnotics
- Drug discovery

FlowCell was founded in 2019 to develop enabling tools for life sciences. The founder Max Narovlyansky, PhD has received his doctorate in microfluidics with one of the pioneers of the field Prof. Whitesides, and has over 15 years of experience in drug development and diagnostics. FlowCell’s vision is to provide tools for precision medicine by eliminating the artificial boundary between drug development and diagnostics.
One of the main tools for precision medicine is companion diagnostics (CDx) -- biological assays that correlate with and predict patient response to treatment options. Selection of the right treatment using biomarkers can dramatically increase response rates.

In cancer, CDx assays have tripled the rate of FDA approvals of new drug applications. We are developing tools CDx of solid tumors, COVID-19 and other areas that require personalized medicine.

Our tools help to increase translational value of drug development. FlowCell’s approach is to focus on development of biomarkers which provides a functional bridge between pre-clinical research and clinical trials.

For pre-clinical research, we supply tools that increase the relevance of the biological models such as organoids grown within micro-physiological systems. Our specialty is microfluidics, which is a gate-keeping technique for working with single cells and other miniaturized complex biological systems. We have partnered with several suppliers of innovative tools in this field.

Our next stage of development includes hardware for measurement of biomarkers in clinical settings (e.g. hospitals). This equipment will cut the size and cost of incumbent technologies tenfold and be capable of measuring cells, proteins, small molecules, electrolytes and gasses.

Precision medicine requires precision data. Our innovative tools will enable development of biomarkers during early research and translation into human trials. We call the entire process bio-computation. Once data of sufficient quantity and precision is available, the problem shifts to bioinformatics. Without these innovative hardware tools, precision medicine will simply be AI processing a completely inadequate amount of data.